ChemoCentryx Stock Loses More Than Half Its Value; Is This The Final Nail For Its Drug?

ChemoCentryx Stock Loses More Than Half Its Value; Is This The Final Nail For Its Drug?
·2 min read

A panel of experts was split Thursday on whether to recommend approval for ChemoCentryx's autoimmune disease drug — and CCXI stock plummeted to its lowest point in two years on Friday.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting